Production (Stage)
Theravance Biopharma, Inc.
TBPH
$9.30
-$0.19-2.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.11% | 12.12% | 15.93% | 20.97% | 26.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.11% | 12.12% | 15.93% | 20.97% | 26.65% |
| Cost of Revenue | 8.11% | -25.80% | -39.15% | -43.02% | -49.71% |
| Gross Profit | 4.49% | 103.78% | 399.01% | 1,554.04% | 653.32% |
| SG&A Expenses | 4.10% | -1.81% | -6.75% | -7.95% | -0.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.67% | -3.83% | -13.42% | -16.03% | -16.32% |
| Operating Income | -9.98% | 20.90% | 38.23% | 43.36% | 44.31% |
| Income Before Tax | -30.02% | 9.45% | 30.46% | 42.91% | 50.79% |
| Income Tax Expenses | 31.68% | 99.26% | 258.88% | 601.04% | 1,981.14% |
| Earnings from Continuing Operations | -30.30% | -2.22% | 18.93% | 32.88% | 40.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.30% | -2.22% | 13.40% | -105.26% | -105.11% |
| EBIT | -9.98% | 20.90% | 38.23% | 43.36% | 44.31% |
| EBITDA | -11.75% | 20.58% | 38.78% | 43.78% | 45.60% |
| EPS Basic | -37.81% | -19.01% | -6.32% | -108.13% | -107.47% |
| Normalized Basic EPS | -27.49% | -0.75% | 21.85% | 26.38% | 30.75% |
| EPS Diluted | -37.81% | -19.01% | -6.32% | -108.13% | -107.47% |
| Normalized Diluted EPS | -27.49% | -0.75% | 21.85% | 26.38% | 30.75% |
| Average Basic Shares Outstanding | -4.81% | -11.75% | -18.34% | -24.27% | -26.72% |
| Average Diluted Shares Outstanding | -4.81% | -11.75% | -18.34% | -24.27% | -26.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |